Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

• Akeso (SEHK:9926) secured regulatory approval in China for ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer.

• The ivonescimab combination regimen is positioned as a new standard of care for advanced squamous NSCLC, with clinical data featured at leading international oncology forums and in peer reviewed publications.

• Akeso reported progress across its bispecific ADC pipeline, including a TROP2/Nectin-4 bispecific ADC candidate, AK146D1.

• The company has started a new Phase II study of AK146D1 in combination with ivonescimab for patients with advanced breast cancer.

Akeso is one of several companies pushing into immuno oncology and AI enabled drug development. Investors may find it useful to compare it with a wider group of healthcare stocks linked to this theme via 133 healthcare AI stocks .

Akeso is a Hong Kong-based biopharmaceutical company with a HK$95.4b market cap that focuses on discovering, developing, manufacturing and commercializing antibody drugs worldwide. The new lung and breast cancer programs sit within its broader push into immuno-oncology and bispecific antibody-drug conjugates.

2 things going right for Akeso that this headline doesn't cover.

Akeso investors get clearer oncology revenue optionality, plus a new breast cancer catalyst

For investors, this approval strengthens the case that Akeso's immuno oncology platform can support a larger commercial footprint in China lung cancer. The key shift is that ivonescimab plus chemotherapy now underpins the lung cancer opportunity as an approved first line standard for advanced squamous NSCLC, rather than a pipeline promise. The new Phase II study for AK146D1 in advanced breast cancer adds a separate, earlier stage catalyst that could widen the addressable market if the IO2.0 plus ADC2.0 combinations continue to generate supportive data.

From here, the most important datapoint to watch is the progression of AK146D1-202 Phase II readouts in advanced breast cancer, especially in HR+/HER2 negative disease and triple negative breast cancer. Those results will help show whether Akeso can extend the ivonescimab franchise meaningfully beyond lung cancer and support a broader multi tumor revenue profile over time.

For the full picture including more risks and rewards, check out the complete Akeso analysis .

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 9926.HK .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com